SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Stephanie Saw

Stephanie Saw

National Cancer Centre Singapore

Dr. Stephanie P.L. Saw is a consultant medical oncologist in the thoracic oncology group at the National Cancer Centre Singapore and an Assistant Professor in the SingHealth Duke-NUS Oncology Academic Clinical Programme. Her research focuses on precision oncology in EGFR-mutated non-small cell lung cancer, including improving risk stratification, for which she earned a PhD from Duke-NUS in 2025 and was awarded an NMRC Transition Award. She co-authored the Asian Thoracic Oncology Research Group consensus on peri-operative management of non-small cell lung cancer and speaks regularly at international congresses including ASCO.

Connect

Stephanie Saw

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates